BioLineRx (BLRX) Long-Term Investments (2017 - 2018)
BioLineRx (BLRX) recorded quarterly Long-Term Investments of $1.0 million in Q1 2018, little changed quarter-over-quarter from $1.0 million in Q4 2017.
BioLineRx (BLRX) Long-Term Investments (2017 - 2018) Analysis & Trends
BioLineRx's Long-Term Investments history runs 2 years deep, the most recent figure standing at $1.0 million for Q1 2018.
- In Q1 2018, Long-Term Investments changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2018 stood at $1.0 million (changed N/A YoY), while the FY2017 annual figure was $1.0 million, changed N/A from the prior year.
- Long-Term Investments was $1.0 million for Q1 2018 at BioLineRx, roughly flat from $1.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $1.0 million in Q4 2017 to a low of -$1.0 million in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 1.00 Mn |
| Dec 31, 2017 | 1.00 Mn |
| Sep 30, 2017 | -1.00 Mn |